Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EGRX NASDAQ:ERNA NASDAQ:GBIO NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$3.03-1.3%$3.29$1.50▼$3.87$39.35M0.836,358 shs857 shsERNAErnexa Therapeutics$1.26+2.9%$1.72$1.21▼$24.30$9.63M5.6542,671 shs54,066 shsGBIOGeneration Bio$5.99+3.6%$4.88$3.00▼$29.10$40.35M2.48795,280 shs46,830 shsPYRGFPyroGenesis Canada$0.19-4.7%$0.28$0.19▼$0.71$35.65M0.8113,493 shs3,168 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals-1.30%-1.94%-5.02%+34.67%-34.27%ERNAErnexa Therapeutics+2.87%-5.64%-25.30%-53.52%-95.12%GBIOGeneration Bio+3.63%-0.17%+39.95%+37.39%-74.29%PYRGFPyroGenesis Canada-4.66%-7.31%-34.38%-48.50%-67.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEGRXEagle Pharmaceuticals$3.03-1.3%$3.29$1.50▼$3.87$39.35M0.836,358 shs857 shsERNAErnexa Therapeutics$1.26+2.9%$1.72$1.21▼$24.30$9.63M5.6542,671 shs54,066 shsGBIOGeneration Bio$5.99+3.6%$4.88$3.00▼$29.10$40.35M2.48795,280 shs46,830 shsPYRGFPyroGenesis Canada$0.19-4.7%$0.28$0.19▼$0.71$35.65M0.8113,493 shs3,168 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEGRXEagle Pharmaceuticals-1.30%-1.94%-5.02%+34.67%-34.27%ERNAErnexa Therapeutics+2.87%-5.64%-25.30%-53.52%-95.12%GBIOGeneration Bio+3.63%-0.17%+39.95%+37.39%-74.29%PYRGFPyroGenesis Canada-4.66%-7.31%-34.38%-48.50%-67.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEGRXEagle Pharmaceuticals 0.00N/AN/AN/AERNAErnexa Therapeutics 0.00N/AN/AN/AGBIOGeneration Bio 2.67Moderate Buy$10.6778.07% UpsidePYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ERNA, GBIO, PYRGF, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.008/13/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $7.008/13/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.007/18/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$50.00 ➝ $70.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEGRXEagle Pharmaceuticals$257.55M0.15$7.58 per share0.40N/A∞ERNAErnexa Therapeutics$580K16.60N/AN/A$0.50 per share2.51GBIOGeneration Bio$19.89M2.03N/AN/A$12.91 per share0.46PYRGFPyroGenesis Canada$9.14M3.90N/AN/A($0.01) per share-19.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AERNAErnexa Therapeutics-$44.54M-$8.31N/A∞N/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)GBIOGeneration Bio-$131.67M-$10.82N/AN/AN/A-341.12%-91.07%-33.65%11/5/2025 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ALatest ERNA, GBIO, PYRGF, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ERNAErnexa TherapeuticsN/A-$0.61N/A-$0.61N/AN/A8/12/2025Q2 2025GBIOGeneration Bio-$2.80-$3.12-$0.32-$3.12$2.51 million$0.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEGRXEagle PharmaceuticalsN/AN/AN/AERNAErnexa TherapeuticsN/A1.811.81GBIOGeneration BioN/A7.517.51PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEGRXEagle Pharmaceuticals85.36%ERNAErnexa Therapeutics70.55%GBIOGeneration Bio95.22%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipEGRXEagle Pharmaceuticals28.90%ERNAErnexa Therapeutics1.50%GBIOGeneration Bio21.80%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataERNAErnexa Therapeutics107.67 million7.56 millionNo DataGBIOGeneration Bio1506.74 million5.27 millionOptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataERNA, GBIO, PYRGF, and EGRX HeadlinesRecent News About These CompaniesHPQ Achieves Pilot-Scale Milestone in Commercial Fumed Silica Production, Sets Sights on Higher-Value Market SegmentSeptember 4 at 10:52 AM | markets.businessinsider.comPyroGenesis’ Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4 at 10:52 AM | markets.businessinsider.comPyroGenesis' Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4 at 7:30 AM | globenewswire.comPyroGenesis Announces Second Quarter 2025 ResultsAugust 6, 2025 | globenewswire.comPyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch TechnologyAugust 5, 2025 | globenewswire.comPyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference CallAugust 1, 2025 | globenewswire.comPyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing CompanyJuly 31, 2025 | globenewswire.comPyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed SilicaJuly 28, 2025 | globenewswire.comPyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata SteelJuly 15, 2025 | globenewswire.comPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production CyclesJuly 8, 2025 | globenewswire.comPyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in EuropeJuly 2, 2025 | globenewswire.comPyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - MorningstarJune 29, 2025 | morningstar.comMPyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 27, 2025 | globenewswire.comPyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global SupplierJune 12, 2025 | globenewswire.comPyroGenesis Announces Extension to Term of WarrantsJune 9, 2025 | globenewswire.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesChevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025How a Superstore Strategy Fueled MINISO’s 20% Stock SurgeBy Jeffrey Neal Johnson | August 26, 2025Low-Cost Global Exposure: 3 Diversified ETFs for Value InvestorsBy Nathan Reiff | September 2, 2025Gold’s Explosive Rally: GDX ETF May Be the Fast Track to ProfitsBy Jeffrey Neal Johnson | September 4, 2025ERNA, GBIO, PYRGF, and EGRX Company DescriptionsEagle Pharmaceuticals NASDAQ:EGRX$3.03 -0.04 (-1.30%) As of 09/5/2025 03:58 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Ernexa Therapeutics NASDAQ:ERNA$1.25 +0.04 (+2.87%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$1.26 +0.01 (+0.80%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Generation Bio NASDAQ:GBIO$5.99 +0.21 (+3.63%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.97 -0.02 (-0.32%) As of 09/5/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.PyroGenesis Canada NASDAQ:PYRGF$0.19 -0.01 (-4.66%) As of 09/5/2025 01:47 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
